Research graph
References from Allogeneic HSCT outcomes and impact of defibrotide prophylaxis on SOS after inotuzumab in pediatric B-ALL. Local targets link to admitted publications; unresolved targets remain external evidence.
Allogeneic stem cell transplantation from HLA-mismatched donors for pediatric patients with acute lymphoblastic leukemia treated according to the 2003 BFM and 2007 International BFM Studies: impact of disease risk on outcomes
10.1016/j.bbmt.2018.05.009 · 2018 · External reference
Hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia
10.1007/s11899-019-00502-2 · 2019 · External reference
Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group
10.1200/jco.2008.17.6065 · 2009 · External reference
Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation
10.1111/bjh.12358 · 2013 · External reference
Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse
10.1016/j.bbmt.2008.11.009 · 2009 · External reference
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study
10.1002/cncr.32116 · 2019 · External reference
Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia
10.1056/nejmoa1509277 · 2016 · External reference
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission
10.1182/blood.2023022330 · 2024 · External reference
Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children's Oncology Group Protocol AALL1621
10.1200/jco.21.01693 · 2022 · External reference
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
10.1038/s41375-018-0265-z · 2019 · External reference
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study
10.1016/s2352-3026(17)30103-5 · 2017 · External reference
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease
10.3324/haematol.2023.284310 · 2024 · External reference
Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia
10.1002/pbc.28718 · 2021 · External reference
A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)
10.1182/blood.2020007848 · 2021 · External reference
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients
10.1038/sj.bmt.1704069 · 2003 · External reference
A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation
2005 · External reference
Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation
10.1038/bmt.2017.161 · 2018 · External reference
Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial
10.1016/s0140-6736(11)61938-7 · 2012 · External reference
Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome
10.1016/j.bbmt.2019.02.018 · 2019 · External reference
Sinusoidal obstruction syndrome (hepatic veno-occlusive disease)
10.1016/j.jceh.2014.10.002 · 2014 · External reference
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome
10.1016/j.bbmt.2009.08.024 · 2010 · External reference
Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors
10.1002/hep.1840040121 · 1984 · External reference
Venoocclusive disease of the liver following bone marrow transplantation
10.1097/00007890-198712000-00011 · 1987 · External reference
Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients
10.7326/0003-4819-118-4-199302150-00003 · 1993 · External reference
Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation
10.1111/bjh.16557 · 2020 · External reference
Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement
10.1016/s2352-3026(19)30201-7 · 2020 · External reference
Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European Compassionate-Use study
2000 · External reference
Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)
10.1038/s41409-019-0474-8 · 2019 · External reference
The use of defibrotide in blood and marrow transplantation
10.1182/bloodadvances.2017008375 · 2018 · External reference
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome
10.1182/blood-2002-04-1216 · 2002 · External reference
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure
10.1182/blood-2015-10-676924 · 2016 · External reference
Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention
10.1038/sj.bmt.1704329 · 2004 · External reference
Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial
10.1016/s2352-3026(23)00011-x · 2023 · External reference
Analytical evaluation of the clonoSEQ assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma
10.1186/s12885-020-07077-9 · 2020 · External reference
Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22(+) acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial
10.3324/haematol.2023.284409 · 2024 · External reference
Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation
10.1038/sj.bmt.1701994 · 1999 · External reference
Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors
10.1038/sj.bmt.1701506 · 1998 · External reference
Incidence of anicteric veno-occlusive disease/sinusoidal obstruction syndrome and outcomes with defibrotide following hematopoietic cell transplantation in adult and pediatric patients
10.1016/j.bbmt.2020.03.011 · 2020 · External reference
Safety of peritoneal and pleural drain placement in pediatric stem cell transplant recipients with severe veno-occlusive disease
10.1111/petr.12730 · 2016 · External reference
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options
10.1038/ng.3362 · 2015 · External reference
Cutting to the front of the line: immunotherapy for childhood acute lymphoblastic leukemia
10.1200/edbk_278171 · 2020 · External reference
Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin
10.3324/haematol.2021.280433 · 2022 · External reference
A systematic review and meta-analysis of studies of defibrotide prophylaxis for veno-occlusive disease/sinusoidal obstruction syndrome
10.1007/s40261-022-01140-y · 2022 · External reference
Prevention of veno-occlusive disease/sinusoidal obstruction syndrome: a never-ending story and no easy answer
10.1038/s41409-023-02007-2 · 2023 · External reference
A meta-analysis evaluating the incidence of bleeding events with intravenous defibrotide treatment outside the veno-occlusive disease/sinusoidal obstruction syndrome setting
10.1177/1076029620935202 · 2020 · External reference
Defibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT)
10.1038/s41409-025-02793-x · 2026 · External reference
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
10.1038/s41375-022-01576-3 · 2022 · External reference
